Discover great EU-funded Innovations
INNOVATION
Method for mapping of engineering outcomes to clinical endpoints for in-silico clinical trials.
SHARE:
Market Maturity: Exploring
These are innovations that are actively exploring value creation opportunities. Learn more
Market Creation Potential
This innovation was assessed by the JRC’s Market Creation Potential indicator framework as addressing the needs of existing markets and existing customers. Learn more
Women-led innovation
A woman had a leadership role in developing this innovation in at least one of the Key Innovator organisations listed below.
Location of Key Innovators developing this innovation
Key Innovators
UN Sustainable Development Goals(SDG)
This innovation contributes to the following SDG(s)
SUSTAINABLE DEVELOPMENT GOAL 3
Ensure healthy lives and promote well-being for all at all ages

The UN explains: "Significant strides have been made in increasing life expectancy and reducing some of the common killers responsible for child and maternal mortality.

Major progress has also been made on increasing access to clean water and sanitation, reducing malaria, tuberculosis, polio and the spread of HIV/AIDS.

However, many more efforts are needed to control a wide range of diseases and address many different persistent and emerging health issues."

The EU-funded Research Project
This innovation was developed under the Horizon 2020 project SIMCOR with an end date of 30/06/2024
  • Read more about this project on CORDIS
Description of Project SIMCOR
The complexity and speed of technological innovation, with increasingly short product cycles, creates huge demand for standardized best practices to apply in-silico validation methods in a statistically robust, repeatable, and efficient way. SIMCor will address this challenge by providing manufacturers of cardiovascular implantable devices with an open, reusable, cloud-based platform for in-silico testing to accelerate development and regulatory approval of their products. The platform will support device validation along the whole R&D pipeline: from initial modelling and in vitro experiments, to animal studies and device implantation and effect simulation on human cohorts. In particular, SIMCor innovative virtual cohort technology will allow to generate and expose new or existing devices to a range of clinically realistic and diversified anatomies and (patho)physiological conditions, also including extensive paediatric populations, meeting the critical need of testing devices in young patients. A standardized multi-level validation process and sensitivity analysis will guarantee statistical credibility for in-silico tests and the platform as a whole, proving solid experimental ground for regulatory authorities, thus accelerating approval and time to market for new products, reducing the burden of human and animal studies and boosting innovation at large. High-priority safety, efficacy and usability endpoints will be investigated, focusing on device implantation and effect simulations in two representative areas: transcatheter aortic valve implantation (TAVI) and pulmonary artery pressure sensors (PAPS). Based on proof-of-validation results and regulatory approval for these use cases, SIMCor will define standard operational procedures (SOPs) and a generalised technical framework for the in-silico testing, validation and regulatory approval of cardiovascular devices, to be put at the service of researchers, medical device manufacturers and regulatory bodies.

Innnovation Radar's analysis of this innovation is based on data collected on 10/09/2024.
The unique id of this innovation in the European Commission's IT systems is: 109334